KRMD vs TNDM
KRMD: Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases, while generating services revenue from pharma partnerships in novel subcutaneous drug development. TNDM: Tandem designs intelligent, consumer-friendly insulin pumps with automated closed-loop technology to help people with insulin-dependent diabetes manage their condition with greater flexibility and less burden.
Side-by-side fundamentals
| Metric | KRMD | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.86 | $16.91 | |
| Market cap as of 2026-07-23 | $177M | $1.2B | |
| Net margin as of 2026-07-23 | -5.3% | -9.2% | KRMD higher |
| Gross margin as of 2026-07-23 | +61.9% | +54.9% | KRMD higher |
| Operating margin as of 2026-07-23 | -6.0% | -8.2% | KRMD higher |
| ROE as of 2026-07-23 | -13.6% | -68.3% | KRMD higher |
| ROA as of 2026-07-23 | -8.3% | -10.0% | KRMD higher |
| Debt / equity as of 2026-07-23 | 0.01 | 4.58 | KRMD lower |
| Revenue growth (YoY) as of 2026-07-23 | +23.3% | +4.5% | KRMD higher |
| Revenue CAGR (3y) SEC XBRL | +13.8% | +8.2% | KRMD higher |
| Beta as of 2026-07-23 | 0.45 | 1.54 | |
| 1-year return as of 2026-07-22 close | +16.5% | +10.5% | KRMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.